Research News

Blood-Based Biomarkers Seen as Breakthrough for Early Diagnosis and Treatment of Alzheimer’s Disease

Newly-Studied REST Protein Provides More Clues to Cause of Alzheimer’s Disease

Exciting news travels from Washington University of St. Louis (WUSL), where two BrightFocus-funded Alzheimer’s researchers recently had their results published in major scientific journals. Both projects were directly funded by BrightFocus.

Recently, the BrightFocus Foundation awarded an Alzheimer’s Disease Research Fellowship to Soong Ho Kim, PhD, at Mount Sinai Hospital in New York City, to study whether a new drug could directly attack symptoms of Alzheimer's disease, but also work to address the disease process. A new study in Molecular Psychiatry now provides evidence that this line of research may be progressing."

Reisa Sperling, MD, a Harvard-based, BrightFocus-funded Alzheimer’s researcher now leading a major clinical trial, thinks it might be possible to prevent or delay the worst symptoms of Alzheimer's when physical changes in the brain, including shrinkage and amyloid build-up, are detected early, before cognition is impaired, and treatment begins at those earliest stages.

After centuries of health and economic disparity, women have emerged as a strong force in the U.S. and worldwide. Yet a crisis of inequality looms ahead.